Visfatin and retinol-binding protein 4 concentrations in lean, glucose-tolerant women with PCOS

Reproductive BioMedicine Online

Volumn 20, Issue 1, 2010, Pages 150-155

  Yildiz, Bulent O ^a   Bozdag, Gurkan ^a   Otegen, Umit ^a   Harmanci, Ayla ^a   Boynukalin, Kubra ^a   Vural, Zehra ^a   Kirazli, Serafettin ^a   Yarali, Hakan ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Insulin resistance; PCOS; Retinol binding protein 4; Visfatin

Indexed keywords

ADIPOCYTOKINE; ANDROGEN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RETINOL BINDING PROTEIN 4; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE TOLERANCE; HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LEAN BODY WEIGHT; OVARY POLYCYSTIC DISEASE; PROTEIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL;

EID: 77149124268     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rbmo.2009.10.016     Document Type: Article

References (38)

1. Abahusain, M.A., Wright, J., Dickerson, J.W., et al., 1999. Retinol, alpha-tocopherol and carotenoids in diabetes. Eur. J. Clin. Nutr. 53, 630-635.
2. Aigner, E., Bachofner, N., Klein, K., et al., 2009. Retinol-binding protein 4 (RBP4) in polycystic ovary syndrome - association with steroid hormones and response to pioglitazone treatment. J. Clin. Endocrinol. Metabol. 94, 1229-1235.
3. Araujo Penna, I., Canella, P.R., Vieira, C.S., et al., 2007. Cardiovascular risk factors are reduced with a low dose of acarbose in obese patients with polycystic ovary syndrome. Fertil. Steril. 88, 519-522.
4. Asuncion, M., Calvo, R.M., San Millan, J.L., et al., 2000. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J. Clin. Endocrinol. Metabol. 85, 2434-2438.
5. Azziz, R., Woods, K.S., Reyna, R., et al., 2004. The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metabol. 89, 2745-2749.
6. Balen, A.H., Laven, J.S., Tan, S.L., et al., 2003. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum. Reprod. Update 9, 505-514.
7. Barber, T.M., Hazell, M., Christodoulides, C., et al., 2008. Serum levels of retinol-binding protein 4 and adiponectin in women with polycystic ovary syndrome: associations with visceral fat but no evidence for fat mass-independent effects on pathogenesis in this condition. J. Clin. Endocrinol. Metabol. 93, 2859-2865.
8. Barber, T.M., McCarthy, M.I., Wass, J.A., et al., 2006. Obesity and polycystic ovary syndrome. Clin. Endocrinol. (Oxf.) 65, 137-145.
9. Carmina, E., Orio, F., Palomba, S., et al., 2006. Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am. J. Med. 119 (356), e1-e6.
10. Chan, T.F., Tsai, Y.C., Chiu, P.R., et al., 2008. Serum retinol-binding protein 4 levels in nonobese women with polycystic ovary syndrome. Fertil. Steril. [e-publication ahead of print November 22].
11. Diamanti-Kandarakis, E., 2008. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Rev. Mol. Med. 10, e3.
12. Diamanti-Kandarakis, E., Kouli, C.R., Bergiele, A.T., et al., 1999. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J. Clin. Endocrinol. Metabol. 84, 4006-4011.
13. Dokras, A., 2008. Cardiovascular disease risk factors in polycystic ovary syndrome. Semin. Reprod. Med. 26, 39-44.
14. Giallauria, F., Orio, F., Palomba, S., et al., 2008. Cardiovascular risk in women with polycystic ovary syndrome. J. Cardiovasc. Med. (Hagerstown) 9, 987-992.
15. Graham, T.E., Wason, C.J., Bluher, M., et al., 2007. Shortcomings in methodology complicate measurements of serum retinol binding protein (RBP4) in insulin-resistant human subjects. Diabetologia 50, 814-823.
16. Graham, T.E., Yang, Q., Bluher, M., et al., 2006. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N. Engl. J. Med. 354, 2552-2563.
17. Guzick, D.S., 1996. Cardiovascular risk in women with polycystic ovarian syndrome. Semin. Reprod. Endocrinol. 14, 45-49.
18. Hahn, S., Backhaus, M., Broecker-Preuss, M., et al., 2007. Retinol-binding protein 4 levels are elevated in polycystic ovary syndrome women with obesity and impaired glucose metabolism. Eur. J. Endocrinol. 157, 201-207.
19. Haider, D.G., Schaller, G., Kapiotis, S., et al., 2006. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 49, 1909-1914.
20. Kowalska, I., Straczkowski, M., Nikolajuk, A., et al., 2007. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Hum. Reprod. 22, 1824-1829.
21. Legro, R.S., 2003. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr. Rev. 24, 302-312.
22. Lopez-Bermejo, A., Chico-Julia, B., Fernandez-Balsells, M., et al., 2006. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 55, 2871-2875.
23. Muoio, D.M., Newgard, C.B., 2005. Metabolism: A is for adipokine. Nature 436, 337-338.
24. Orio Jr., F., Palomba, S., Cascella, T., et al., 2004. Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? Reprod. BioMed. Online 9, 505-510.
25. Ozkaya, M., Cakal, E., Ustun, Y., et al., 2008. Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. Fertil. Steril. [e-publication ahead of print 24 December].
26. Panidis, D., Farmakiotis, D., Rousso, D., et al., 2008. Plasma visfatin levels in normal weight women with polycystic ovary syndrome. Eur. J. Intern. Med. 19, 406-412.
27. Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19, 41-47.
28. Shroff, R., Kerchner, A., Maifeld, M., et al., 2007. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. J. Clin. Endocrinol. Metabol. 92, 4609-4614.
29. Tan, B.K., Chen, J., Digby, J.E., et al., 2006. Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin. J. Clin. Endocrinol. Metabol. 91, 5022-5028.
30. Tan, B.K., Chen, J., Lehnert, H., et al., 2007. Raised serum, adipocyte, and adipose tissue retinol-binding protein 4 in over-weight women with polycystic ovary syndrome: effects of gonadal and adrenal steroids. J. Clin. Endocrinol. Metabol. 92, 2764-2772.
31. von Eynatten, M., Humpert, P.M., 2008. Retinol-binding protein-4 in experimental and clinical metabolic disease. Expert Rev. Mol. Diagn. 8, 289-299.
32. Vural, B., Caliskan, E., Turkoz, E., et al., 2005. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum. Reprod. 20, 2409-2413.
33. Wang, J.X., Norman, R.J., 2004. Risk factors for the deterioration of glucose metabolism in polycystic ovary syndrome. Reprod. BioMed. Online 9, 201-204.
34. Weiping, L., Qingfeng, C., Shikun, M., et al., 2006. Elevated serum RBP4 is associated with insulin resistance in women with polycystic ovary syndrome. Endocrine 30, 283-287.
35. Yang, Q., Graham, T.E., Mody, N., et al., 2005. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436, 356-362.
36. Yarali, H., Yildiz, B.O., Demirol, A., et al., 2002. Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. Hum. Reprod. 17, 289-294.
37. Yildiz, B.O., Haznedaroglu, I.C., Kirazli, S., et al., 2002. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J. Clin. Endocrinol. Metabol. 87, 3871-3875.
38. Zwirska-Korczala, K., Sodowski, K., Konturek, S.J., et al., 2008. Postprandial response of ghrelin and PYY and indices of low-grade chronic inflammation in lean young women with polycystic ovary syndrome. J. Physiol. Pharmacol. 59 (Suppl. 2), 161-178.